kabutan

WAKAMOTO PHARMA, Last Fiscal Year's Undisclosed Ordinary Loss to Widen

Fri Apr 25, 2025 4:00 pm JST Revision

4512 WAKAMOTO PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Guidance Update Report

WAKAMOTO PHARMACEUTICAL CO.,LTD. <4512> [TSE Std] announced a previously undisclosed earnings forecast after the market closed on April 25th (16:00). The ordinary loss (non-consolidated) for the fiscal year ending March 2025 is expected to expected to be loss of 407 million yen (compared to a loss of 161 million yen in the previous period).

Kabutan News

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 Prev ー ー ー ー － 3 Mar 25, 2025 J-GAAP
Oct - Mar, 2024 New 3,969 -180 -151 191 5.5 3 Apr 25, 2025 J-GAAP
Revision Rate － － － － －

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 Prev ー ー ー ー － 3 Mar 25, 2025 J-GAAP
Mar, 2025 New 7,780 -456 -407 50 1.4 3 Apr 25, 2025 J-GAAP
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 4,120 133 158 330 9.6 3 May 15, 2024 J-GAAP
Oct - Mar, 2024 Guidance 3,969 -180 -151 191 5.5 3 Apr 25, 2025 J-GAAP
YoY -3.7% － － -42.1% -42.5%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 8,660 141 242 138 4.0 3 May 15, 2023 J-GAAP
Mar, 2024 7,738 -195 -161 108 3.1 3 May 15, 2024 J-GAAP
Mar, 2025 Guidance 7,780 -456 -407 50 1.4 3 Apr 25, 2025 J-GAAP
YoY +0.5% -133.8% -152.8% -53.7% -54.0%

Related Articles